Investing Ideas
/
Norwegian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Norwegian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

1 companies

Vistin Pharma

Market Cap: NOK 988.9m

Through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide.

VISTN

NOK 22.30

1.8%

-3.0%